The ACME Laboratories Ltd. (DSE:ACMELAB)
79.50
-0.50 (-0.63%)
At close: Nov 12, 2026
The ACME Laboratories Revenue
In the fiscal year ending June 30, 2026, The ACME Laboratories had annual revenue of 41.60B BDT with 15.75% growth. The ACME Laboratories had revenue of 11.13B in the quarter ending June 30, 2026, with 16.18% growth. That makes The ACME Laboratories the 13,862nd largest company in the world by revenue and 17th in Bangladesh.
Revenue
41.60B
Revenue Growth
+15.75%
P/S Ratio
0.40
Revenue / Employee
4.61M
Employees
9,025
Market Cap
16.82B
Revenue by Geography
- Bangladesh 38.90B 94.1%
- Export 2.44B 5.9%
- Others 965.72K 0.0%
Fiscal year ended Jun 30, 2025 See the full The ACME Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 41.60B | 5.66B | 15.75% |
| Jun 30, 2025 | 35.94B | 4.01B | 12.54% |
| Jun 30, 2024 | 31.93B | 4.98B | 18.49% |
| Jun 30, 2023 | 26.95B | 3.09B | 12.95% |
| Jun 30, 2022 | 23.86B | 3.09B | 14.87% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beximco Pharmaceuticals PLC. | 56.27B |
| Renata | 47.49B |
| Beacon Pharmaceuticals | 16.43B |
| The IBN SINA Pharmaceutical Industry | 13.90B |
| Navana Pharmaceuticals | 10.57B |
| Unilever Consumer Care | 3.29B |
| Techno Drugs | 3.10B |
| Orion Pharma | 3.01B |